ReviewFrontiers in cardiovascular medicine2022
Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes.
Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of incident heart failure after COVID-19 recovery: a systematic review and meta-analysis.Heart failure reviews · 2023Pooled it
- The regulatory mechanisms and translational applications of non-coding RNA in SARS-CoV-2 infection-related cardiovascular pathology.Frontiers in cardiovascular medicine · 2026Review
- Impact of Coronavirus Disease 2019 on Sick Sinus Syndrome: Trends in Incidence and Pacemaker Implantation.The Journal of innovations in cardiac rhythm management · 2025Article
- Two-year follow-up of patients with myocardial injury during acute COVID-19: insights from the CARDIO COVID 20-21 registry.Frontiers in cardiovascular medicine · 2025Article
- COVID-19 worsens quality of life in elderly heart failure patients: a clinical study.American journal of translational research · 2025Article
- Measurement of Cardiac-Specific Biomarkers in the Emergency Department: New Insight in Risk Evaluation.International journal of molecular sciences · 2023Review
- [Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management].Revista espanola de cardiologia · 2023Article
- Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management.Revista espanola de cardiologia (English ed.) · 2023Article
- Prevalence and impact of myocardial injury among patients hospitalized with COVID-19.Frontiers in cardiovascular medicine · 2023Article
- Association between pre-existing cardiovascular disease, mortality and cardiovascular outcomes in hospitalised patients with COVID-19.Frontiers in cardiovascular medicine · 2023Article
- Two-dimensional Speckle-Tracking and Four-dimensional Echocardiographic Evaluation of Cardiac Involvement in Post-COVID-19 patients: Comparison of Symptomatic and Asymptomatic Groups.Journal of cardiovascular echographyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a pandemic with high mortality and morbidity rates. Clinical manifestation is widely variable, including asymptomatic or mild respiratory tract illness to severe pneumonia and death. Myocardial injury is a significant pathogenic feature of COVID-19 and it is associated with worse in-hospital outcomes, mainly due to a higher number of hospital readmissions, with over 50% mortality. These findings suggest that myocardial injury would identify COVID-19 patients with higher risk during active infection and mid-term follow-up. Potential contributors responsible for myocardial damage are myocarditis, vasculitis, acute inflammation, type 1 and type 2 myocardial infarction. However, there are few data about cardiac sequelae and its long-term consequences. Thus, the optimal screening tool for residual cardiac sequelae, clinical follow-up, and the benefits of a specific cardiovascular therapy during the convalescent phase remains unknown. This mini-review explores the different mechanisms of myocardial injury related to COVID-19 and its short and long-term implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.